Levofloxacină Infomed (Levofloxacin)

Levofloxacin is a fluoroquinolone antibiotic indicated for several serious bacterial infections.

• Community‑acquired pneumonia: achieves bacterial eradication and clinical cure in adult patients, leading to symptom resolution.
• Hospital‑acquired pneumonia: provides broad coverage against typical and atypical pathogens, improving outcomes and reducing hospital stay.
• Complicated urinary tract infections: resolves infection and prevents recurrence in complicated cases, supporting renal function.
• Skin and soft‑tissue infections: reduces bacterial load and promotes healing of severe infections, decreasing tissue damage.
• Septicemia: contributes to rapid clearance of bacteremia and supports recovery, decreasing mortality risk.

• Levofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By binding to the quinolone‑resistance‑determining region of these enzymes, it prevents the unwinding of DNA, halting transcription and bacterial cell division. This bactericidal action is concentration‑dependent and effective against a broad spectrum of Gram‑negative and Gram‑positive organisms. The drug penetrates well into respiratory tissues, urinary tract, skin and bloodstream, achieving therapeutic concentrations at infection sites.

Levofloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Diarrhea
• Headache
• Dizziness

Serious or Rare Side Effects

• Tendon rupture or inflammation
• QT interval prolongation leading to arrhythmia
• Clostridioides difficile‑associated colitis
• Severe allergic reactions such as anaphylaxis

Before initiating therapy with Levofloxacină Infomed, clinicians should consider several precautionary measures.

• Assess renal function: adjust dosage in patients with impaired clearance.
• Review cardiac history: avoid in patients with known QT prolongation or arrhythmias.
• Evaluate tendon health: discontinue if patient experiences tendon pain or inflammation.
• Monitor for C. difficile infection: watch for severe diarrhea during and after treatment.
• Avoid use in patients with known hypersensitivity to fluoroquinolones.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levofloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Co‑administration with other QT‑prolonging agents: increased risk of cardiac arrhythmia.
• Concurrent use with warfarin: may enhance anticoagulant effect and raise INR.
• Combination with systemic corticosteroids: heightened risk of tendon rupture.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs: may increase central nervous system stimulation.
• Theophylline: levofloxacin can raise plasma theophylline levels, risking toxicity.
• Cyclosporine: may increase risk of seizures when used together.